+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Comparison of the Effects of Althesin and Sodium Pentobarbitone on the Regional Uptake of 2-Deoxyglucose by the Brain and Pituitary Gland of the Rat: Selective Effects on Pars intermedia

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          The uptake of radiolabelled 2-deoxyglucose (2DG) was used to compare the effects ofthe steroid anaesthetic, Althesin (alphaxalone plus alphadolone acetate) with those of sodium pentobarbitone on the regional metabolism of the brain and pituitary gland. Experiments were carried out on adult female Wistar rats. Studies on conscious animals were carried out with the aid of an indwelling intra-atrial catheter. The uptake of 2DG was measured both by liquid scintillation spectroscopy of <sup>3</sup>H-2DG in tissue blocks and by quantitative autoradiography with <sup>14</sup>C-2DG Both anaesthetics significantly reduced uptake of <sup>3</sup>H-2DG in the frontal, parietal and occipital cortex, and striatum and thalamus, but <sup>3</sup>H-2DG uptake was significantly increased in the pituitary gland. Similar effects were found by measuring <sup>14</sup>C-2DG uptake, and this technique showed further that Althesin, but not sodium pentobarbitone, selectively increased (2-fold) the uptake of <sup>14</sup>C-2DG by the pars intermedia. The increase in <sup>I4</sup>C-2DG uptake by the pars intermedia in animals anaesthetized with Althesin was significantly reduced by a lesion placed in the arcuate nucleus. The most likely explanation for the effects of Althesin on the pars intermedia is that this anaesthetic increases the activity of arcuate neurons that innervate the pars intermedia.

          Related collections

          Author and article information

          S. Karger AG
          28 March 2008
          : 38
          : 3
          : 237-242
          MRC Brain Metabolism Unit, University Department of Pharmacology, Edinburgh, Scotland
          123897 Neuroendocrinology 1984;38:237–242
          © 1984 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 6
          Original Paper


          Comment on this article